Pneumococcal Vaccination in Immunocompromised Hosts: An Update

Froneman, Claire; Kelleher, Peter; José, Ricardo J.

doi:10.3390/vaccines9060536

Cited by 6 publications

(2 citation statements)

References 73 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This raises the possibility of using alternative test vaccination strategies to interrogate immune competence and, that with better vaccine design and protocols, immune responses to existing non‐SARS‐CoV‐2 vaccines may be improved in immunocompromised cohorts. Furthermore, as pneumococcal polysaccharide vaccination becomes widely adopted in haemato‐oncology management guidelines [ 26 ], immunologists must be cognizant of the intersection between therapeutic vaccination and test vaccination, in particular, the potential for vaccine hyporesponsiveness through repeat exposure to pneumococcal vaccinations [ 27 , 28 ].…”

Section: Discussionmentioning

confidence: 99%

Clinical and laboratory characteristics of patients with symptomatic secondary immunodeficiency following the treatment of haematological malignancies

Shields

Faustini

Young

et al. 2023

eJHaem

View full text Add to dashboard Cite

Secondary immunodeficiency (SID), manifesting as increased susceptibility to infection, is an emergent clinical problem in haematoncology. Management of SID includes vaccination, prophylactic antibiotics (pAbx) and immunoglobulin replacement therapy (IgRT). We report clinical and laboratory parameters of 75 individuals, treated for haematological malignancy, who were referred for immunological assessment due to recurrent infections. Forty‐five were managed with pAbx while thirty required IgRT after failing to improve on pAbx. Individuals requiring IgRT had significantly more bacterial, viral and fungal infections resulting in hospitalization at least 5 years after their original haemato‐oncological diagnosis. Following immunological assessment and intervention, a 4.39‐fold reduction in the frequency of hospital admissions to treat infection was observed in the IgRT cohort and a 2.30‐fold reduction in the pAbx cohort. Significant reductions in outpatient antibiotic use were also observed in both cohorts following immunology input. Patients requiring IgRT were more hypogammaglobulinaemic and had lower titres of pathogen‐specific antibodies and smaller memory B cell populations than those requiring pAbx. Test vaccination with pneumococcal conjugate vaccine discriminated poorly between the two groups. Patients requiring IgRT could be distinguished by combining wider pathogen‐specific serology with a frequency of hospital admissions for infection. If validated in larger cohorts, this approach may circumvent the need for test vaccination and enhance patient selection for IgRT.

show abstract

Section: Discussionmentioning

confidence: 99%

Clinical and laboratory characteristics of patients with symptomatic secondary immunodeficiency following the treatment of haematological malignancies

Shields

Faustini

Young

et al. 2023

eJHaem

View full text Add to dashboard Cite

show abstract

“…PCV13 should be administered initially followed by PPV23 8 weeks later ( 125 ). However, if PPV23 has been given prior to PCV13 as part of the diagnostic work-up of antibody deficiency, most groups recommend addition of PCV13 ≥1 year later ( 126 ).…”

Section: Pneumococcal Vaccination Recommendations In Different Patien...mentioning

confidence: 99%

A comprehensive overview of pneumococcal vaccination recommendations for adults in South Africa, 2022

Feldman¹,

Dlamini²,

Richards³

et al. 2022

J Thorac Dis

View full text Add to dashboard Cite

Pneumococcal infections remain a common global cause of significant morbidity and mortality.The first recommendations for adult pneumococcal vaccination, published in South Africa in 1999, contained information only on the 23-valent polysaccharide vaccine (PPV23). With the introduction of the 13-valent pneumococcal conjugate vaccine (PCV13) for use in adults and the perceived uncertainty that most clinicians had regarding use of these vaccines in adults, these vaccine recommendations were updated in 2022. A Working Group, which consisted of individuals in various fields of medical practice in South Africa, who were from different areas of the country, and included clinicians from both the public and private sectors, was assembled to revise the recommendations. The expertise of the participants varied widely, dependent on their training and specialty, and encompassed different organ systems, disease conditions, and/or practice types. Each participant was allocated a different section, based on their expertise, for which they were required to do an extensive review of the current literature and write their section. The entire working group then reviewed the complete document several times, following additional comments and recommendations. This update contains recommendations for the use of both PPV23 and PCV13, either alone, or in sequence, both in vaccine naïve and in previously vaccinated individuals. It includes both age and risk categories, and encompasses the elderly (≥65 years), as well as younger adults (<65 years

show abstract

IgG antibody response to pneumococcal-conjugated vaccine (Prevenar®13) in children with immunodeficiency disorders

Garrido-Jareño

Sahuquillo-Arce

Rodríguez-Vega

et al. 2023

Med Microbiol Immunol

View full text Add to dashboard Cite

show abstract

Pneumococcal Vaccination in Immunocompromised Hosts: An Update

Cited by 6 publications

References 73 publications

Clinical and laboratory characteristics of patients with symptomatic secondary immunodeficiency following the treatment of haematological malignancies

Clinical and laboratory characteristics of patients with symptomatic secondary immunodeficiency following the treatment of haematological malignancies

A comprehensive overview of pneumococcal vaccination recommendations for adults in South Africa, 2022

IgG antibody response to pneumococcal-conjugated vaccine (Prevenar®13) in children with immunodeficiency disorders

Contact Info

Product

Resources

About